What is HC Wainwright’s Estimate for JAZZ Q1 Earnings?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Jazz Pharmaceuticals in a note issued to investors on Monday, March 10th. HC Wainwright analyst O. Livnat forecasts that the specialty pharmaceutical company will post earnings of $3.45 per share for the quarter. HC Wainwright has a “Buy” rating and a $217.00 price objective on the stock. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $16.96 per share. HC Wainwright also issued estimates for Jazz Pharmaceuticals’ Q2 2025 earnings at $5.47 EPS, Q3 2025 earnings at $5.64 EPS and Q4 2025 earnings at $6.20 EPS.

Several other equities analysts have also issued reports on the company. Morgan Stanley reissued an “overweight” rating and issued a $183.00 price target (up from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 7th. JPMorgan Chase & Co. upped their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Cantor Fitzgerald lowered Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and upped their target price for the stock from $140.00 to $150.00 in a research report on Wednesday, February 26th. Robert W. Baird upped their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. Finally, UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price target for the company from $145.00 to $179.00 in a research report on Friday, March 7th. One analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of “Buy” and an average price target of $190.53.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $134.16 on Thursday. The business’s 50 day simple moving average is $128.92 and its 200 day simple moving average is $120.49. Jazz Pharmaceuticals has a one year low of $99.06 and a one year high of $148.06. The stock has a market capitalization of $8.15 billion, a PE ratio of 18.90, a PEG ratio of 1.04 and a beta of 0.44. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Institutional Trading of Jazz Pharmaceuticals

Several large investors have recently modified their holdings of JAZZ. Fuller & Thaler Asset Management Inc. grew its holdings in Jazz Pharmaceuticals by 117.4% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company’s stock valued at $115,681,000 after purchasing an additional 507,234 shares during the period. Darwin Global Management Ltd. bought a new stake in Jazz Pharmaceuticals during the fourth quarter valued at about $59,668,000. Dimensional Fund Advisors LP grew its position in shares of Jazz Pharmaceuticals by 18.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock worth $250,619,000 after purchasing an additional 320,724 shares in the last quarter. Ameriprise Financial Inc. raised its stake in Jazz Pharmaceuticals by 20.9% during the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock valued at $225,076,000 after purchasing an additional 315,608 shares during the period. Finally, GMT Capital Corp lifted its holdings in Jazz Pharmaceuticals by 140.0% in the 4th quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company’s stock worth $62,659,000 after purchasing an additional 296,800 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Insider Activity at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 4,813 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.42, for a total value of $695,093.46. Following the sale, the chief accounting officer now directly owns 8,237 shares in the company, valued at approximately $1,189,587.54. This trade represents a 36.88 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Robert Iannone sold 7,080 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $138.60, for a total value of $981,288.00. Following the sale, the chief marketing officer now owns 82,024 shares in the company, valued at $11,368,526.40. This represents a 7.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 28,736 shares of company stock valued at $4,022,825. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.